Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1986 Sep;45(9):726–731. doi: 10.1136/ard.45.9.726

Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.

A W van Rijthoven, B A Dijkmans, H S Goei The, J Hermans, Z L Montnor-Beckers, P C Jacobs, A Cats
PMCID: PMC1001977  PMID: 3532966

Abstract

The efficacy and safety of cyclosporin for patients with rheumatoid arthritis (RA) were assessed in a six month double blind, placebo controlled, multicentre study. The initial dosage of the drug was 10 mg/kg daily for two months. There were many discontinuations in both the cyclosporin group (eight out of 17) and the placebo group (six out of 19). Of the patients who completed the six months of therapy, those who had received cyclosporin showed a significant improvement in the number of swollen joints, the Ritchie articular index, and pain at active movement and at rest, compared not only with their condition at the start of the study, but also with the end results of the placebo group. Major adverse reactions to the drug were gastrointestinal disturbances and nephrotoxicity, which were probably due to the relatively high dosages of cyclosporin given in combination with non-steroidal anti-inflammatory drugs.

Full text

PDF
731

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berry H., Liyanage S., Durance R., Barnes C. G., Berger L. Trial comparing azathioprine and penicillamine in treatment of rheumatoid arthritis [proceedings]. Ann Rheum Dis. 1976 Dec;35(6):542–543. doi: 10.1136/ard.35.6.542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Borel J. F. Cyclosporin-A--present experimental status. Transplant Proc. 1981 Mar;13(1 Pt 1):344–348. [PubMed] [Google Scholar]
  3. Breedveld F. C., Valentijn R. M., Westedt M. L., Weening J. J. Rapidly progressive glomerulonephritis with glomerular crescent formation in rheumatoid arthritis. Clin Rheumatol. 1985 Sep;4(3):353–359. doi: 10.1007/BF02031622. [DOI] [PubMed] [Google Scholar]
  4. Chapman J. R., Griffiths D., Harding N. G., Morris P. J. Reversibility of cyclosporin nephrotoxicity after three months' treatment. Lancet. 1985 Jan 19;1(8421):128–130. doi: 10.1016/s0140-6736(85)91902-6. [DOI] [PubMed] [Google Scholar]
  5. Ciabattoni G., Cinotti G. A., Pierucci A., Simonetti B. M., Manzi M., Pugliese F., Barsotti P., Pecci G., Taggi F., Patrono C. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. N Engl J Med. 1984 Feb 2;310(5):279–283. doi: 10.1056/NEJM198402023100502. [DOI] [PubMed] [Google Scholar]
  6. Donatsch P., Abisch E., Homberger M., Traber R., Trapp M., Voges R. A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay. 1981;2(1):19–32. doi: 10.1080/01971528108062989. [DOI] [PubMed] [Google Scholar]
  7. HAMILTON E. B., SCOTT J. T. Hydroxychloroquine sulfate ("plaguenil") in treatment of rheumatoid arthritis. Arthritis Rheum. 1962 Oct;5:502–512. doi: 10.1002/art.1780050507. [DOI] [PubMed] [Google Scholar]
  8. Henderson B., Staines N. A., Burrai I., Cox J. H. The anti-arthritic and immunosuppressive effects of cyclosporine on arthritis induced in the rat by type II collagen. Clin Exp Immunol. 1984 Jul;57(1):51–56. [PMC free article] [PubMed] [Google Scholar]
  9. Hess A. D., Tutschka P. J., Pu Z., Santos G. W. Effect of cyclosporin A on human lymphocyte responses in vitro. IV. Production of T cell stimulatory growth factors and development of responsiveness to these growth factors in CsA-treated primary MLR cultures. J Immunol. 1982 Jan;128(1):360–367. [PubMed] [Google Scholar]
  10. Iannuzzi L., Dawson N., Zein N., Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med. 1983 Oct 27;309(17):1023–1028. doi: 10.1056/NEJM198310273091704. [DOI] [PubMed] [Google Scholar]
  11. Kimberly R. P., Bowden R. E., Keiser H. R., Plotz P. H. Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med. 1978 May;64(5):804–807. doi: 10.1016/0002-9343(78)90520-x. [DOI] [PubMed] [Google Scholar]
  12. Klippel J. H., Decker J. L. Methotrexate in rheumatoid arthritis. N Engl J Med. 1985 Mar 28;312(13):853–854. doi: 10.1056/NEJM198503283121310. [DOI] [PubMed] [Google Scholar]
  13. Nussenblatt R. B., Palestine A. G., Chan C. C., Mochizuki M., Yancey K. Effectiveness of cyclosporin therapy for Behçet's disease. Arthritis Rheum. 1985 Jun;28(6):671–679. doi: 10.1002/art.1780280611. [DOI] [PubMed] [Google Scholar]
  14. Sigler J. W., Bluhm G. B., Duncan H., Sharp J. T., Ensign D. C., McCrum W. R. Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med. 1974 Jan;80(1):21–26. doi: 10.7326/0003-4819-80-1-21. [DOI] [PubMed] [Google Scholar]
  15. Stiller C. R., Dupré J., Gent M., Jenner M. R., Keown P. A., Laupacis A., Martell R., Rodger N. W., von Graffenried B., Wolfe B. M. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science. 1984 Mar 30;223(4643):1362–1367. doi: 10.1126/science.6367043. [DOI] [PubMed] [Google Scholar]
  16. Sun D. C., Roth S. H., Mitchell C. S., Englund D. W. Upper gastrointestinal disease in rheumatoid arthritis. Am J Dig Dis. 1974 May;19(5):405–410. doi: 10.1007/BF01255603. [DOI] [PubMed] [Google Scholar]
  17. Weinblatt M. E., Coblyn J. S., Fox D. A., Fraser P. A., Holdsworth D. E., Glass D. N., Trentham D. E. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985 Mar 28;312(13):818–822. doi: 10.1056/NEJM198503283121303. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES